Clinical Rheumatology

, Volume 33, Issue 9, pp 1347–1349 | Cite as

Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag

  • Phillip Scheinberg
  • Cristiane Carvalho Singulane
  • Luis Sergio Guedes Barbosa
  • Morton ScheinbergEmail author
Case Based Review


Eltrombopag is a new thrombomimetic medication approved for the treatment of immune thrombocytopenia. There are very few reports on the use of eltrombopag in patients with thrombocytopenia associated with sytemic lupus.We present a recent case of a patient with lupus with severe thrombocytopenia refractory to conventional therapy and full recovery with the use of eltrombopag. The present status of the literature with the use of this medication in patients with lupus is reviewed and discussed.


Eltrombopag Lupus Thrombocytopenia 





  1. 1.
    Bashal F (2013) Hematological disorders in patients with systemic lupus erythematosus. Open Rheumatol J 7:87–95PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Provan D, Stasi R, Newland AC et al (2010) International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115:168–186PubMedCrossRefGoogle Scholar
  3. 3.
    Keeling DM, Isenberg DA (1993) Haematological manifestations of systemic lupus erythematosus. Blood Rev 7:199–207PubMedCrossRefGoogle Scholar
  4. 4.
    Hallam S, Provan D, Newland AC (2013) Immune thrombocytopenia—what are the new treatment options? Expert Opin Biol Ther 13:1173–1185PubMedCrossRefGoogle Scholar
  5. 5.
    Imbach P, Crowther M (2011) Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med 365:734–741PubMedCrossRefGoogle Scholar
  6. 6.
    Alkaabi JK, Alkindi S, Riyami NA et al (2012) Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic lupus erythematosus. Lupus 21:1571–1574PubMedCrossRefGoogle Scholar
  7. 7.
    Cela I, Miller IJ, Katz RS et al (2010) Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE). Clin Adv Hematol Oncol 8:806–809PubMedGoogle Scholar
  8. 8.
    Kuter DJ, Begley CG (2002) Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 100:3457–3469PubMedCrossRefGoogle Scholar
  9. 9.
    Olnes MJ, Scheinberg P, Calvo KR et al (2012) Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 367:11–19PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Kremer J, Li ZG, Hall S et al (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159:253–261PubMedGoogle Scholar
  11. 11.
    Li J, Yang C, Xia Y et al (2001) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98:3241–3248PubMedCrossRefGoogle Scholar
  12. 12.
    Cheng G, Saleh MN, Marcher C et al (2011) Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 377:393–402PubMedCrossRefGoogle Scholar
  13. 13.
    Bussel JB, Cheng G, Saleh MN et al (2007) Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357:2237–2247PubMedCrossRefGoogle Scholar
  14. 14.
    Saleh MN, Bussel JB, Cheng G et al (2013) Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 121:537–545PubMedCrossRefGoogle Scholar
  15. 15.
    Kuter DJ, Bussel JB, Newland A et al (2013) Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 161:411–423PubMedCrossRefGoogle Scholar
  16. 16.
    Kuter DJ, Rummel M, Boccia R et al (2010) Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 363:1889–1899PubMedCrossRefGoogle Scholar
  17. 17.
    Bussel JB, Kuter DJ, George JN et al (2006) AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 355:1672–1681PubMedCrossRefGoogle Scholar
  18. 18.
    Fain O, Ebbo M, Khellaf M et al (2013) Prolonged remission after TPO-receptor agonist discontinuation in adults with chronic ITP. Results of a French Observational Study. Blood 122:327Google Scholar
  19. 19.
    Qin P, Qiu J, Shao L et al (2013) Sustained complete remission of corticosteroid-resistant immune thrombocytopenia with a short course of recombinant human thrombopoietin. Blood 122:4746CrossRefGoogle Scholar
  20. 20.
    Desmond R, Townsley DM, Dumitriu B, et al (2014) Eltrombopag restores tri-lineage hematopoiesis in refractory severe aplastic anemia which can be sustained on discontinuation of drug. Blood 123:1818Google Scholar

Copyright information

© Clinical Rheumatology 2014

Authors and Affiliations

  • Phillip Scheinberg
    • 1
  • Cristiane Carvalho Singulane
    • 2
  • Luis Sergio Guedes Barbosa
    • 2
  • Morton Scheinberg
    • 3
    Email author
  1. 1.Hematology Service, Oncology CenterHospital São JoséSão PauloBrazil
  2. 2.Rheumatology SectionFederal University of Mato GrossoCuiabaBrazil
  3. 3.Rheumatologist Hospital Israelita Albert EinsteinSão PauloBrazil

Personalised recommendations